Related Experiment Video
Updated: Aug 14, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications
1Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen, Norway.
Cancer Chemotherapy and Pharmacology
|January 1, 1990
Summary
Aminoglutethimide, an aromatase inhibitor for breast cancer, boosts drug metabolism and oestrone sulphate clearance. This may contribute to its therapeutic effect by reducing oestrogen available to tumor cells.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Aminoglutethimide is an established aromatase inhibitor for advanced breast cancer treatment.
- The drug is known to induce hepatic mixed-function oxidases, affecting the metabolism of various medications.
- Oestrone sulphate is a potential substrate for tumour cells in breast cancer.
Purpose of the Study:
- To investigate the effect of aminoglutethimide on oestrone sulphate metabolism.
- To explore the potential role of altered oestrone sulphate metabolism in the mechanism of action of aminoglutethimide.
Main Methods:
- The study likely involved measuring plasma clearance rates of oestrone sulphate in patients or in vitro models.
- Analysis of drug metabolism induction by aminoglutethimide was assessed through drug interactions.
Main Results:
- Aminoglutethimide significantly increases the plasma clearance rate of oestrone sulphate.
- The drug also enhances the metabolism of other substances like warfarin, digitoxin, antipyrine, and theophylline due to increased hepatic mixed-function oxidase activity.
Conclusions:
- Increased metabolism of oestrone sulphate by aminoglutethimide may be a key component of its efficacy in treating advanced breast cancer.
- Aminoglutethimide's impact on drug metabolism necessitates careful consideration of drug interactions during patient treatment.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...